olfactory receptor family 56 subfamily B member 1Genealiases: OR11-65 · OR56B1P
Q-omics provides the consensus-scored OR56B1 profile across patient tissues and cancer cell-line models. OR56B1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OR56B1 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, OR56B1 RNA expression shows 8,860 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight ACC, KIRC, and LAML as cancer lineages where OR56B1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR56B1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR56B1 survival associations across molecular data types. OR56B1 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR56B1 RNA expression–survival associations across cancer types. High OR56B1 expression shows unfavorable associations in ACC, UVM and OV, but favorable associations in CESC, LIHC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OR56B1 RNA expression.
This table summarizes OR56B1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR56B1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR56B1 shows lower tumor expression in LUSC, LUAD and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher OR56B1 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p < 0.001).
This table shows molecular features associated with OR56B1 in patient tissues and cancer cell lines. In patient samples, OR56B1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, OR56B1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and STOMACH.
